The 134 references in paper , статья Редакционная (2014) “Современные ингаляционные устройства для лечения респираторной патологии: отчет рабочей группы Европейского респираторного общества и Международного общества по использованию аэрозолей в медицине // Current inhalational devices for treatment of respiratory disease. Task Force report of European Respiratory Society and the International Societyfor Aerosols in Medicine” / spz:neicon:pulmonology:y:2011:i:6:p:17-41

1
Global Initiative for Asthma (GINA), National Heart Lung and Blood Institute, National Institutes of Health. GINA report. Global strategy for asthma management and prevention. Bethesda: National Institutes of Health; 2006.
(check this in PDF content)
2
Global Initiative for Obstructive Lung Disease (GOLD), National Heart Lung and Blood Institute, National Institutes of Health. GOLD report. Global strategy for diagnosis, management and prevention of COPD. Bethesda: National Institutes of Health; 2009.
(check this in PDF content)
3
BTS / SIGN. British guidelines on the management of asthma. London; Edinburgh: British Thoracic Society and Scottish Intercollegiate Guidelines Network; 2008.
(check this in PDF content)
4
Flume P.A., O'Sullivan B.P., Robinson K.A. et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 2007; 176: 957–969.
(check this in PDF content)
5
Heijerman H., Westerman E., Conway S. et al.Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J. Cyst. Fibros. 2009; 8: 295–315.
(check this in PDF content)
6
Brocklebank D., Ram F., Wright J. et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airway disease; a systematic review of the literature. Hlth Technol. Assoc. 2001; 5: 1–149.
(check this in PDF content)
7
Dolovich M.B., Ahrens R.C., Hess D.R. et al.Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians / American College of Asthma, Allergy, and Immunology. Chest 2005; 127: 335–371.
(check this in PDF content)
8
Crompton G.K., Barnes P.J., Broeders M. et al.The need to improve inhalation technique in Europe: a report by the Aerosol Drug Management Improvement Team. Respir. Med. 2006; 100: 1479–1494.
(check this in PDF content)
9
Chrystyn H., Price D. Not all asthma inhalers are the same: factors to consider when prescribing a new inhaler. Prim. Care Respir. J. 2009; 18: 243–249.
(check this in PDF content)
10
Molimard M., Raherison C., Lignot M. et al.Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J. Aerosol Med. 2003; 16: 249–254.
(check this in PDF content)
11
Lavorini F., Magnan A., Dubus J.C. et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir. Med. 2008; 102: 593–604.
(check this in PDF content)
12
Crompton G.K. Problems patients have using pressurized aerosol inhalers. Eur. J. Respir. Dis. 1982; 63: 101–104.
(check this in PDF content)
13
Labiris N.R., Dolovich M.B. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 2003; 56 (6): 588–599.
(check this in PDF content)
14
Köbrich R., Rudolf G., Stahlhofen W. A mathematical model of mass deposition in man. Ann. Occup. Hyg. 1994; 38: 15–23.
(check this in PDF content)
15
Williamson I.J., Matusiewicz S.P., Brown P.H. et al. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur. Respir. J. 1995; 8: 590–592.
(check this in PDF content)
16
Newman S.P., Pavia D., Garland N. et al. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur. J. Respir. Dis. Suppl 1982; 63: 57–65.
(check this in PDF content)
17
Usmani O.S., Biddiscombe M.F., Barnes P.J.Regional lung deposition and bronchodilator response as a function of beta-2 agonist particle size. Am. J. Respir. Crit. Care Med. 2005; 172: 1497–1504.
(check this in PDF content)
18
Pauwels R., Newman S., Borgstrom L.Airway deposition and the airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur. Respir. J. 1997; 10: 2127–2138.
(check this in PDF content)
19
Laube B.L.In vivo measurements of aerosol dose and distribution: clinical relevance. J. Aerosol Med. 1996; 9 (Suppl. 1): S77–S91.
(check this in PDF content)
20
Laube B.L. The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination. Respir. Care 2005; 50: 1162–1176.
(check this in PDF content)
21
Ilowite J.S., Gorvoy J.D., Smaldone G.C.Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am. Rev. Respir. Dis. 1987; 136: 1445–1449.
(check this in PDF content)
22
Dolovich M., Sanchis J., Rossman C. et al. Aerosol penetrance: a sensitive index of peripheral airways obstruction. J. Appl. Physiol. 1976; 40: 468–471.
(check this in PDF content)
23
Dolovich M., Killian D., Wolff R. et al.Pulmonary aerosol deposition in chronic bronchitis: IPPB versus quiet breathing. Am. Rev. Respir. Dis. 1977; 115: 397–402.
(check this in PDF content)
24
Carstairs H.R., Nimmo A.J., Barnes P.J. Autoradiographic visualization of b-adrenoceptor subtype in human lung. Am. Rev. Respir. Dis. 1985; 132: 541–547.
(check this in PDF content)
25
Mak J.C., Barnes P.J. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am. Rev. Respir. Dis. 1990; 141: 1559–1568.
(check this in PDF content)
26
Adcock I.M., Gilbey T., Gelder C.M. et al. Glucocorticoid receptor localization in normal and asthmatic lung. Am. J. Respir. Crit. Care Med. 1996; 154: 771–782.
(check this in PDF content)
27
Hogg J.C., Chu F., Utokaparch S. et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 2645–2653.
(check this in PDF content)
28
Barnes P.J. Corticosteroids: the drugs to beat. Eur. J. Pharmacol. 2006; 533: 2–14.
(check this in PDF content)
29
Chua H.L., Collis G.G., Newbury A.M. et al. The influence of age on aerosol deposition in children with cystic fibrosis. Eur. Respir. J. 1994; 7: 2185–2191.
(check this in PDF content)
30
Brennan V.K., Osman L., Graham H. et al.Device compliance: the need to consider both competence and contrivance. Respir. Med. 2005; 99: 97–102.
(check this in PDF content)
31
Shim C., Williams M.H. The adequacy of inhalation of aerosol from canister nebulizers. Am. J. Med. 1980; 69: 891–894.
(check this in PDF content)
32
Stoloff S.W., Stempel D.A., Meyer J. et al.Improved refill persistence with fluticasone propionate and salmeterol in 39 a single inhaler compared with other controller therapies. J. Allergy Clin. Immunol. 2004; 113: 245–251.
(check this in PDF content)
33
Charles T., Quinn D., Weatherall M. et al.An audiovisual reminder function improves adherence with inhaled corticosteroid therapy in asthma. J. Allergy Clin. Immunol. 2007; 119: 811–816.
(check this in PDF content)
34
Chapman K.R., Voshaar T.H., Virchow J.C. Inhaler choice in primary care. Eur. Respir. Rev. 2005; 14: 117–122.
(check this in PDF content)
35
Broeders M.E., Sanchis J., Levy M.L. et al.The ADMIT series – Issues in inhalation therapy. 2) Improving technique and clinical effectiveness. Prim. Care Respir. J. 2009; 18: 76–82.
(check this in PDF content)
36
Maugh T.H. 2nd. FDA phasing out asthma inhalers using CFC propellant. http://latimesblogs.latimes.com/booster_ shots/2010/04/the-fda-phasing-out-certain-asthmainhalers.htmlDate last updated: April 13, 2010. Date last accessed: March, 29, 2011.
(check this in PDF content)
37
Gabrio B.J., Stein S.W., Velsaquez D.J.A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int. J. Pharm. 1999; 186: 3–12.
(check this in PDF content)
38
Leach C.L., Davidson P.J., Boudreau R.J. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. J. 1998; 12: 1346–1353.
(check this in PDF content)
39
Leach C.L., Davidson P.J., Hasselquist B.E. et al.Lung deposition of hydrofluoroalkane 134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross over study in healthy volunteers. Chest 2002; 122: 510–516.
(check this in PDF content)
40
Busse W.W., Brazinsky S., Jacobson K. et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J. Allergy Clin. Immunol.1999; 104: 1215–1222.
(check this in PDF content)
41
Leach C.L., Davidson P.J., Hasselquist B.E. et al. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone for a metered dose inhaler. J. Aerosol Med. 2005; 18: 379–385.
(check this in PDF content)
42
Bousquet J., Poli G., Acerbi D. et al.Systemic exposure and implications for lung deposition with extrafine hydrofluroalkane beclomethasone dipropionate / formoterol combinations. Clin. Pharmacokinet. 2009; 48: 347–358.
(check this in PDF content)
43
Papi A., Paggiaro P., Nicolini G. et al. Beclomethasone/formoterol vs fluticasone / salmeterol inhaled combination in moderate to severe asthma. Allergy 2007; 62: 1182–1188.
(check this in PDF content)
44
Papi A., Paggiaro P.L., Nicolini G. et al.Beclomethasone / formoterol versus budesonide / formoterol combination therapy in asthma. Eur. Respir. J. 2007; 29: 682–689.
(check this in PDF content)
45
Newman S.P., Weisz A.W., Talaee N. et al. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991; 46: 712–716.
(check this in PDF content)
46
Fergusson R.J., Lenney J., McHardy G.J. et al.The use of a new breath-actuated inhaler by patients with severe airflow obstruction. Eur. Respir. J. 1991; 4: 172–174.
(check this in PDF content)
47
Barry P.W., O'Callaghan C. Inhalational drug delivery from seven different spacer devices. Thorax 1996; 51: 835–840.
(check this in PDF content)
48
Richards J., Hirst P., Pitcairn G. et al.Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J. Aerosol Med. 2001; 14: 197–208.
(check this in PDF content)
49
Roller C.M., Zhang G., Troedson R.G. et al.Spacer inhalation technique and deposition of extrafine aerosol in asthmatic children. Eur. Respir. J. 2007; 29: 299–306.
(check this in PDF content)
50
Devadason S.G., Huang T., Walker S. et al. Distribution of technetium-99m-labelled QVAR delivered using an Autohaler device in children. Eur. Respir. J. 2003; 21: 1007–1011.
(check this in PDF content)
51
Lavorini F., Fontana G. Targeting drugs to the airways: the role of spacer devices. Exp. Opin. Drug Deliv. 2009; 6: 91–102.
(check this in PDF content)
52
Cohen H.A., Cohen Z., Pomeranz A.S. et al.Bacterial contamination of spacer devices used by asthmatic children. J. Asthma 2005; 42: 169–172.
(check this in PDF content)
53
Cole C.H. Special problems in aerosol delivery: neonatal and pediatric considerations. Respir. Care 2000; 45: 646–651.
(check this in PDF content)
54
Wildhaber J.H., Waterer G.W., Hall G.L. et al.Reducing electrostatic charge on spacer devices and bronchodilator response. Br. J. Clin. Pharmacol. 2000; 50: 277–280.
(check this in PDF content)
55
Pierart F., Wildhaber J.H., Vrancken I. et al.Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur. Respir. J. 1999; 13: 673–678.
(check this in PDF content)
56
Janssens H.M., Heijnen E.M.E.W., Jong de V.M. et al. Aerosol delivery from spacers in wheezy infants aged 0 to 2 years in daily life. Eur. Respir. J. 2000; 16: 850–856.
(check this in PDF content)
57
Barry P.W., O'Callaghan C.The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Br. J. Clin. Pharmacol. 1995; 40: 76–78.
(check this in PDF content)
58
Schulte M., Osseiran K., Betz R. et al. Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD. J. Aerosol Med. Pulm. Drug Deliv. 2008; 21: 321–328.
(check this in PDF content)
59
Moore A.C., Stone S. Meeting the needs of patients with COPD: patients' preference for the Diskus inhaler compared with the Handihaler. Int. J. Clin. Pract. 2004; 58: 444–450.
(check this in PDF content)
60
Wilson D.S., Gillion M.S., Rees P.J. Use of dry powder inhalers in COPD. Int. J. Clin. Pract. 2007; 61: 2005–2008.
(check this in PDF content)
61
Meakin B.J., Cainey J.M., Woodcock P.M.Simulated ''in use'' and ''mis-use'' aspects of the delivery of terbutaline sulphate from the Bricanyl TurbohalerTM dry powder inhaler. Int. J. Pharm. 1995; 119: 103–108.
(check this in PDF content)
62
Clark A.R., Hollingworth A.M. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers – implications for in vitro testing. J. Aerosol Med. 1993; 6: 99–110.
(check this in PDF content)
63
Chrystyn H. Effects of device design on patient compliance: comparing the same drug in different devices. In: Dalby R.N., Byron P.R., Peart J. et al., eds. Respiratory drug delivery Europe 2009. River Grove, Davis Healthcare International Publishing; 2009: 105–116.
(check this in PDF content)
64
Chrystyn H., Price D.What you need to know about inhalers and how to use them. Prescriber 2009; 20: 47–52.
(check this in PDF content)
65
Everard M.L., Devadason S.G., Le Souëf P.N.Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir. Med. 1997; 91: 624–628.
(check this in PDF content)
66
Kamin W.E.S., Genz T., Roeder S. et al. Mass output and particle size distribution of glucocorticosteroids emitted from different inhalation devices depending on various inspiratory parameters. J. Aerosol. Med. 2002; 15: 65–73.
(check this in PDF content)
67
Pedersen S., Hansen O.R., Fuglsang G.Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch. Dis. Child. 1990; 65: 308–319.
(check this in PDF content)
68
Fenton C., Keating G.M., Plosker G.L.Novolizer: a multidose dry powder inhaler. Drugs 2003; 63: 2437–2445. Современные ингаляционные устройства для лечения респираторной патологии 40
(check this in PDF content)
69
Koskela T., Malmström K., Sairanen U. et al. Efficacy of salbutamol via Easyhaler unaffected by low inspiratory flow. Respir. Med. 2000; 94: 1229–1233.
(check this in PDF content)
70
Newhouse M.T., Nantel N.P., Chambers C.B. et al. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. Chest 1995; 115: 952–956.
(check this in PDF content)
71
Nielsen K.G., Auk I.L., Bojsen K. et al. Clinical effect of Diskus drypowder inhaler at low and high inspiratory flow rates in asthmatic children. Eur. Respir. J. 1998; 11: 350–354.
(check this in PDF content)
72
Chodosh S., Flanders J.S., Kesten S. et al.Effective delivery of particles with the Handihaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J. Aerosol. Med. 2001; 14: 309–315.
(check this in PDF content)
73
Nielsen K.G., Skov M., Klug B. et al. Flow dependent effect of formoterol dry-powder inhaled from Aerolizer. Eur. Respir. J. 1997; 10: 2105–2109.
(check this in PDF content)
74
Bentur L., Mansour Y., Hamzani Y. et al. Measurement of inspiratory flow in children. Pediatr. Pulmonol. 2004; 38: 304–307.
(check this in PDF content)
75
Jarvis S., Ind P.W., Shiner R.J. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age and Ageing 2007; 36: 213–218.
(check this in PDF content)
76
Pedersen S. How to use a rotahaler. Arch. Dis. Child. 1986; 61: 11–14.
(check this in PDF content)
77
Boe L., Dennis J.H., O'Driscoll B.R. et al.European Respiratory Society task force on the use of nebulizers. Eur. Respir. J. 2001; 18: 228–242.
(check this in PDF content)
78
Smith E.C., Denyer J., Kendrick A.H. Comparison of 23 nebulizer / compressor combinations for domiciliary use. Eur. Respir. J. 1995; 8: 1214–1221.
(check this in PDF content)
79
Kendrick A.H., Smith E.C., Wilson R.S.E.Selecting and using nebulizer equipment. Thorax 1997; 52: S92–S101.
(check this in PDF content)
80
Brand P., Beckmann H., Maas Enriquez M. et al. Peripheral deposition of a1-protease inhibitor using commercial inhalation devices. Eur. Respir. J. 2003; 22: 263–267.
(check this in PDF content)
81
Niven R.W., Ip A.Y., Mittleman S. et al.Some factors associated with the ultrasonic nebulization of proteins. Pharmacol. Res. 1995; 12: 53–59.
(check this in PDF content)
82
Munster A.M., Benstrup E., Jensen J.I. et al. Jet and ultrasonic nebulization of chain urokinase plasminogen activator (scu-PA). J. Aerosol. Med. 2000; 13: 325–333.
(check this in PDF content)
83
Denyer J., Nikander K., Smith N.J. Adaptive aerosol delivery (AAD) technology. Expert. Opin. Drug. Deliv. 2004; 1: 165–176.
(check this in PDF content)
84
Wagner A., Vorauer-Uhl K., Katinger H. Nebulization of liposomal rh-Cu/Zn-SOD with a novel vibrating membrane nebulizer. J. Liposome Res. 2006; 16: 113–125.
(check this in PDF content)
85
Elhissi A.M., Karnam K.K., Danesh-Azari M.R. et al. Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers. J. Pharm. Pharmacol. 2006; 58: 887–894.
(check this in PDF content)
86
Kleemann E., Schemhl T., Geesler T. et al. Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability. Pharmacol. Res. 2007; 24: 277–287.
(check this in PDF content)
87
Johnson J., Waldrep J.C., Guo J. et al.Aerosol delivery of recombinant human DNAse I: in vitro comparison of a vibrating mesh nebulizerwith a jet nebulizer. Respir. Care 2008; 53: 1703–1708.
(check this in PDF content)
88
Smaldone G.C., Berg E., Nikander K. Variation in pediatric aerosol delivery: importance of facemask. J. Aerosol Med. 2005; 18: 354–363.
(check this in PDF content)
89
Sangwan S., Gurses B.K., Smaldone G.C.Face masks and facial deposition of aerosols. Pediatr. Pulmonol. 2004; 37: 447–452.
(check this in PDF content)
90
Erzinger S., Schueepp K.G., Brooks-Wildhaber J. et al. Face masks and aerosol delivery in vivo. J. Aerosol Med. 2007; 20 (Suppl. 1): S78–S84.
(check this in PDF content)
91
Smaldone G.C., Sangwan S., Shah A. Face mask design, facial deposition, and delivered dose of nebulized aerosols. J. Aerosol Med. 2007; 20 (Suppl. 1): S66–S77.
(check this in PDF content)
92
National Asthma Education and Prevention Program, National Institutes of Health: Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda: National Institutes of Health; 2007.
(check this in PDF content)
93
Zierenberg B., Eicher J., Dunne S. et al.Boehringer Ingelheim nebulizer BINEB1 a new approach to inhalation therapy. In: Dalby R., Byron P.R., Farr S.J., eds. Respiratory Drug Delivery V. Buffalo Grove: Interpharm Press; 1996: 187–193.
(check this in PDF content)
94
Zierenberg B. Optimizing the in vitro performance of Respimat. J. Aerosol Med. 1999; 12: S19–S24.
(check this in PDF content)
95
Newman S.P., Steed K.P., Reader S.J. Efficient delivery to the lungs of flunisolide aerosol from a new portable handheld multidose nebulizer. J. Pharm. Sci. 1996; 85: 960–964.
(check this in PDF content)
96
Newman S.P., Brown J., Steed K.P. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines. Comparison of Respimat1 Soft MistTM Inhaler with conventional pMDIs with and without spacer devices. Chest 1998; 113: 957–963.
(check this in PDF content)
97
Steed K.P., Towse L.J., Freund B. et al. Lung and oropharyngeal depositions of fenoterol hydrobromide delivered from the prototype III hand-held multidose Respimat nebuliser. Eur. J. Pharm. Sci. 1997; 5: 55–61.
(check this in PDF content)
98
Bateman E.D., Boushey H.A., Bousquet J. et al. GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am. J. Respir. Crit. Care Med. 2004; 170: 836–844.
(check this in PDF content)
99
Donaldson S.H., Bennett W.D., Zeman K.L. et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med. 2006; 354: 241–250.
(check this in PDF content)
100
Kesser K.C., Geller D.E.New aerosol delivery devices for cystic fibrosis. Respir. Care 2009; 54: 754–767.
(check this in PDF content)
101
Lipworth B.J. Treatment of acute asthma. Lancet 1997; 350: 18–23.
(check this in PDF content)
102
Corbridge T.C., Hall J.B. The assessment and management of adults with status asthmaticus. Am. J. Respir. Crit. Care Med. 1995; 151: 1296–1316.
(check this in PDF content)
103
Salmeron S., Taravella O., Bard M. et al. Modes d'administration des b-agonistes dans l'asthme. [Modes of administration of bagonists in asthma.]. Rev. Pneumol. Clin. 1996; 52: 119–127.
(check this in PDF content)
104
Hendeles L., Hatton R.C., Coors T.J. et al.Automatic replacement of albuterol nebulizer therapy by metereddose inhaler and valved holding chamber. Am. J. Hlth Syst. Pharm. 2005; 62: 1053–1061.
(check this in PDF content)
105
Jasper A.C., Mohsenifar Z., Kahan S. et al. Cost benefit comparison of aerosol bronchodilator delivery methods in hospitalized patients. Chest 1987; 91: 614–618.
(check this in PDF content)
106
Turner J.R., Corkery K.J., Eckman D.E. et al. Equivalence of continuous flow nebuliser and metered dose inhaler with reservoir bag for treatment of acute airflow obstruction. Chest 1988; 93: 476–481.
(check this in PDF content)
107
Mestitz H., Copland J.M., McDonald C.F.Comparison of outpatient nebulized vs. metered dose inhaler terbutaline in chronic airflow obstruction. Chest 1989; 96: 1237–1240. 41
(check this in PDF content)
108
Shortfall S.P., Blum J., Oldenburg F.A. et al. Treatment of patients hospitalized for exacerbations of chronic obstructive pulmonary disease: comparison of an oral / metereddose inhaler regimen and an intravenous/nebulizer regimen. Respir. Care 2002; 47: 154–158.
(check this in PDF content)
109
Robinson T.D., Freiberg D.B., Regnis J.A. et al. The role of hypoventilation and ventilation-perfusion redistribution in oxygen-induced hypercapnia during acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1524–1529.
(check this in PDF content)
110
Durrington H.J., Flubacher M., Ramsay C.F. et al. Initial oxygen management in patients with an exacerbation of chronic obstructive pulmonary disease. Quart. J. Med. 2005; 98: 499–504.
(check this in PDF content)
111
Zhang L., Mendoza-Sassi R.A., Wainwright C. et al. Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst. Rev. 2008; 4: CD006458.
(check this in PDF content)
112
Lenney W., Boner A.L., Bont L. et al.Medicines used in respiratory diseases only seen in children. Eur. Respir. J. 2009; 34: 531–551.
(check this in PDF content)
113
European Medicines Agency. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD). www.ema.europa.eu/pdfs/ human/ewp/4850108en.pdf Date last updated: March 19, 2008. Date last accessed: March 24, 2011.
(check this in PDF content)
114
Cates C.J., Crilly J.A., Rowe B.H.Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst. Rev. 2006; 2: CD000052.
(check this in PDF content)
115
Dhand R. Inhalation therapy with metered-dose inhalers and dry powder inhalers in mechanically ventilated patients. Respir. Care 2005; 50: 1331–1345.
(check this in PDF content)
116
Dhand R., Duarte A.G., Jubran A. et al. Dose-response to bronchodilator delivered by metered-dose inhaler in ventilatorsupported patients. Am. J. Respir. Crit. Care Med. 1996; 154: 388–393.
(check this in PDF content)
117
Fink J.B., Dhand R., Duarte A.G. et al. Aerosol delivery from a metered-dose inhaler during mechanical ventilation. An in vitro model. Am. J. Respir. Crit. Care Med. 1996; 154: 382–387.
(check this in PDF content)
118
Mouloudi E., Katsanoulas K., Anastasaki M. et al. Bronchodilator delivery by metered dose inhaler in mechanically ventilated COPD patients: influence of tidal volume. Intens. Care Med. 1999; 25: 1215–1221.
(check this in PDF content)
119
Waldrep J.C., Keyhani K., Black M. et al.Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol. Chest 1994; 105: 106–110.
(check this in PDF content)
120
Hess D.R., Dillman C., Kacmarek R.M. In-vitro evaluation of aerosol bronchodilator delivery during mechanical ventilation: pressure-control versus volume control ventilation. Intens. Care Med. 2003; 29: 1145–1150.
(check this in PDF content)
121
Vecellio L., Guerin C., Grimbert D. et al. In vitro study and semiempirical model for aerosol delivery control during mechanical ventilation. Intens. Care Med. 2005; 31: 871–876.
(check this in PDF content)
122
O'Riordan T.G., Greco M.J., Perry R.J. et al. Nebulizer function during mechanical ventilation. Am. Rev. Respir. Dis. 1992; 145: 1117–1122.
(check this in PDF content)
123
Miller D.D., Amin M.M., Palmer L.B. et al. Aerosol delivery and modern mechanical ventilation: in vitro / in vivo evaluation. Am. J. Respir. Crit. Care Med. 2003; 168: 1205–1209.
(check this in PDF content)
124
Goode M.L., Fink J.B., Dhand R. et al.Improvement in aerosol delivery with helium-oxygen mixture during mechanical ventilation. Am. J. Respir. Crit. Care Med. 2001; 163: 109–114.
(check this in PDF content)
125
Duarte A.G., Momii K., Bidani A. Bronchodilator therapy with metered-dose inhaler and spacer versus nebulizer in mechanically-ventilated patients: comparison of magnitude and duration of response. Respir. Care 2000; 45: 817–823.
(check this in PDF content)
126
Manthous C.A., Hall J.B., Schmidt G.A. et al.Metereddose inhaler versus nebulized albuterol in mechanicallyventilated patients. Am. Rev. Respir. Dis. 1993; 148: 1567–1570.
(check this in PDF content)
127
Bernasconi M., Brandolese R., Poggi R. et al.Doseresponse effects and time course of effects of inhaled fenoterol on respiratory mechanics and arterial oxygen tension in mechanically ventilated patients with chronic airflow obstruction. Intens. Care Med. 1990; 16: 108–114.
(check this in PDF content)
128
Putensen C., Hormann C., Kleinsasser A. et al. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 1998; 157: 1743–1747.
(check this in PDF content)
129
Walmrath D., Schneider T., Schermuly R. et al. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 1996; 153: 991–996.
(check this in PDF content)
130
Hess D.R. The mask for noninvasive ventilation: principles of design and effects on aerosol delivery. J. Aerosol Med. 2007; 20 (Suppl. 1): S85–S99.
(check this in PDF content)
131
Branconnier M.P., Hess D.R.Albuterol delivery during noninvasive ventilation. Respir. Care 2005; 50: 1649–1653.
(check this in PDF content)
132
Calvert L.D., Jackson J.M., White J.A. et al.Enhanced delivery of nebulised salbutamol during non-invasive ventilation. J. Pharm. Pharmacol. 2006; 58: 1553–1557.
(check this in PDF content)
133
Haughney J., Price D., Barnes N.C. et al.Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir. Med. 2010; 104: 1237–1245.
(check this in PDF content)
134
Thomas M., Price D., Chrystyn H. et al.Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. B.M.C. Pulm. Med. 2009; 9: 1. Поступила 12.12.11 УДК 615.032.23
(check this in PDF content)